Palatin Technologies (PTN) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PTN shares.
View PTN analyst ratings or view top-rated stocks.

2 brokerages have issued 1-year price objectives for Palatin Technologies' shares. Their PTN share price forecasts range from $50.00 to $70.00. On average, they anticipate the company's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 2,566.7% from the stock's current price.
View analysts price targets for PTN or view top-rated stocks among Wall Street analysts.

Palatin Technologies' stock was trading at $3.87 at the beginning of the year. Since then, PTN stock has decreased by 41.9% and is now trading at $2.25.
View the best growth stocks for 2023 here.

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings data on Tuesday, May, 16th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.24. The biopharmaceutical company had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.09 million. Palatin Technologies had a negative net margin of 766.11% and a negative trailing twelve-month return on equity of 278.73%. During the same quarter last year, the firm posted ($0.75) earnings per share.

Shares of Palatin Technologies reverse split on Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM).

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Palatin Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.34%), Montis Financial LLC (0.19%), Susquehanna International Group LLP (0.17%), CIBC Asset Management Inc (0.13%) and Dimensional Fund Advisors LP (0.11%). Insiders that own company stock include Alan W Dunton and Robert K Deveer Jr.
View institutional ownership trends.

Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PTN stock can currently be purchased for approximately $2.25.

Palatin Technologies (NYSEAMERICAN:PTN) has a market capitalization of $25.09 million and generates $1.47 million in revenue each year. The biopharmaceutical company earns $-36,200,000.00 in net income (profit) each year or ($2.96) on an earnings per share basis.

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The official website for the company is www.palatin.com. The biopharmaceutical company can be reached via phone at (609) 495-2200, via email at investors@palatin.com, or via fax at 609-495-2202.